487 related articles for article (PubMed ID: 26432382)
21. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
[TBL] [Abstract][Full Text] [Related]
22. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Lee HJ; Daver N; Kantarjian HM; Verstovsek S; Ravandi F
Clin Cancer Res; 2013 Jan; 19(2):327-35. PubMed ID: 23209034
[TBL] [Abstract][Full Text] [Related]
23. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
24. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms.
Montero P; Milara J; Roger I; Cortijo J
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207510
[TBL] [Abstract][Full Text] [Related]
25. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
26. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
27. Tools and methods for studying the Drosophila JAK/STAT pathway.
Chen Q; Giedt M; Tang L; Harrison DA
Methods; 2014 Jun; 68(1):160-72. PubMed ID: 24685392
[TBL] [Abstract][Full Text] [Related]
28. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
29. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
Lee K; Evans MG; Yang L; Ng S; Snowden C; Khodadoust M; Brown RA; Trum NA; Querfeld C; Doan LT; Song J; Zhang H; Gru AA; Wood GS; Wada DA; Shanmugam V; Haun PL; Aster JC; Duncan LM; Guitart J; Weinstock DM; Nardi V; Choi J
Blood; 2021 Dec; 138(23):2435-2440. PubMed ID: 34432866
[TBL] [Abstract][Full Text] [Related]
30. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
31. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
32. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.
Groner B; von Manstein V
Mol Cell Endocrinol; 2017 Aug; 451():1-14. PubMed ID: 28576744
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
34. The JAK/STAT signaling cascade in gastric carcinoma (Review).
Khanna P; Chua PJ; Bay BH; Baeg GH
Int J Oncol; 2015 Nov; 47(5):1617-26. PubMed ID: 26398764
[TBL] [Abstract][Full Text] [Related]
35. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
36. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
37. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
38. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
[TBL] [Abstract][Full Text] [Related]
39. JAK/STAT in leukemia: a clinical update.
Liang D; Wang Q; Zhang W; Tang H; Song C; Yan Z; Liang Y; Wang H
Mol Cancer; 2024 Jan; 23(1):25. PubMed ID: 38273387
[TBL] [Abstract][Full Text] [Related]
40. The identification and characterization of a STAT5 gene signature in hematologic malignancies.
Sonkin D; Palmer M; Rong X; Horrigan K; Regnier CH; Fanton C; Holash J; Pinzon-Ortiz M; Squires M; Sirulnik A; Radimerski T; Schlegel R; Morrissey M; Cao ZA
Cancer Biomark; 2015; 15(1):79-87. PubMed ID: 25524945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]